血府逐瘀制剂治疗乳腺增生症的系统评价

目的:系统评价血府逐瘀制剂治疗乳腺增生症的有效性,为临床合理应用该类制剂提供循证参考。方法:计算机检索中国生物医学文献数据库、中文科技期刊全文数据库、万方数据库、中国期刊全文数据库、Embase及MedLine等数据库,收集血府逐瘀制剂(汤剂、胶囊及口服液)联合其他治疗手段(观察组)与其他药物联合其他治疗手段或随访(对照组)的随机对照试验。在质量评价与文献提取的基础上,采用统计软件RevMan 5.3进行文献荟萃分析。结果:最终将7篇文献纳入此次研究,共871例患者。Meta分析结果显示,观察组患者的有效率(OR=4.62,95%CI=3.08~6.93,P〈0.000 01)、治愈率[OR=...

Full description

Saved in:
Bibliographic Details
Published in中国医院用药评价与分析 Vol. 17; no. 12; pp. 1663 - 1666
Main Author 买雪婷;滕亮;王钰博;马雪英;杨东亮
Format Journal Article
LanguageChinese
Published 新疆医科大学药学院,新疆乌鲁木齐,830011%新疆医科大学第一附属医院药学部,新疆乌鲁木齐,830011 2017
Subjects
Online AccessGet full text
ISSN1672-2124
DOI10.14009/j.issn.1672-2124.2017.12.028

Cover

More Information
Summary:目的:系统评价血府逐瘀制剂治疗乳腺增生症的有效性,为临床合理应用该类制剂提供循证参考。方法:计算机检索中国生物医学文献数据库、中文科技期刊全文数据库、万方数据库、中国期刊全文数据库、Embase及MedLine等数据库,收集血府逐瘀制剂(汤剂、胶囊及口服液)联合其他治疗手段(观察组)与其他药物联合其他治疗手段或随访(对照组)的随机对照试验。在质量评价与文献提取的基础上,采用统计软件RevMan 5.3进行文献荟萃分析。结果:最终将7篇文献纳入此次研究,共871例患者。Meta分析结果显示,观察组患者的有效率(OR=4.62,95%CI=3.08~6.93,P〈0.000 01)、治愈率[OR=2.83,95%CI=1.94~4.13,P〈0.000 01(6篇文献);OR=2.32,95%CI=1.54~3.49,P〈0.000 1(剔除异质性研究后的5篇文献)]明显优于对照组,差异均有统计学意义。结论:与其他药物联合其他治疗手段比较,血府逐瘀制剂联合其他治疗手段治疗乳腺增生症更有效。
Bibliography:Xuefuzhuyu ; Cyclomastopathy ; Efficacy ; Cure rate ; Meta analysis
MAI Xueting1, TENG Liang2, WANG Yubo2, MA Xueying1, YANG Dongliang2 (1. College of Pharmacy, Xinjiang Medical University, Xinjiang Urumqi 830011, China; 2. Dept. of Pharmacy, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Urumqi 830011, China)
11-4975/R
OBJECTIVE: To systematically review the effectiveness of Xuefuzhuyu preparation in treatment of cyclomastopathy, so as to provide evidence-based references for the rational application of this kind of preparations. METHODS: CBM, VIP, Wanfang database, CNKI, Embase and MedLine were retrieved to collect randomized controlled trials between Xuefuzhuyu preparation (decoction, capsule and oral liquid) combined with other treatment (observation group) and other drugs combined with some therapeutic options or follow up (control group). On the basis of quality evaluation and literature extraction, the RevMan 5.3 was adopted to conduct Meta analysis. RESULTS: 7 studies were involve
ISSN:1672-2124
DOI:10.14009/j.issn.1672-2124.2017.12.028